Tirzepatide or the Operating Room: How Long Does a Drug Trial Get?
He clearly qualifies for surgery. The real disagreement is whether a genuinely potent pharmacologic option deserves a real, time-bounded trial first — and what happens if nobody sets the terms of that trial in advance.
Marcus D., a 42-year-old man, owns a small neighborhood bakery he opens at 4am six days a week, work that keeps him on his feet nine hours a day but hasn't moved the needle on his weight the way he once assumed physical work would. He has had type 2 diabetes for eleven years, currently on metformin and basal insulin at 60 units nightly, with an A1c that has settled at 9.5% despite reported adherence; his BMI is 44, and he was diagnosed with moderate obstructive sleep apnea two years ago, now on nightly CPAP. What worries him most, when the conversation turns to bariatric surgery, isn't the procedure itself — it's the six-week recovery window a surgeon has quoted him, and what that means for a bakery that has no other full-time employee.
His numbers already clear the threshold most guidelines use for surgical referral without argument: a BMI over 40 with poorly controlled diabetes on maximal reasonable insulin dosing. The real question the team is working through isn't whether he's a surgical candidate — he clearly is — it's whether a genuinely potent pharmacologic option deserves a real, bounded trial first, given how far that option has moved in the last several years. SURMOUNT-2, the tirzepatide trial run specifically in patients with type 2 diabetes rather than obesity alone, showed roughly 15% body weight loss at the highest studied dose alongside substantial A1c reduction — numbers that would have been unthinkable for an injectable non-surgical option a decade ago, and close enough to surgical outcomes that "try the drug first" is no longer an obviously weaker option on the merits, only a genuinely contested one.
Deciding what "try the drug first" actually means
Start tirzepatide before finalizing a surgical date. SURMOUNT-2, run in patients with type 2 diabetes specifically, showed roughly 15% weight loss and real A1c improvement at the top dose — numbers that have genuinely narrowed the gap with surgical outcomes. Given his stated concern about recovery time and staffing his own business, a non-surgical option with this much current evidence behind it deserves a real trial, not a courtesy mention on the way to the OR.
I'd weigh durability more heavily than the trial's headline number. The STAMPEDE trial's five-year follow-up found surgical patients maintaining substantially better glycemic control than those on intensive medical therapy, and anatomic weight-loss surgery doesn't carry the same erosion risk over time that pharmacologic weight loss has historically shown once a drug is stopped or its effect plateaus.
Tirzepatide is newer and better than the medical-therapy comparators STAMPEDE actually used, I'll grant that directly — but "newer and better than the old comparator" isn't the same claim as "durable at five years," and we don't have that data for tirzepatide yet. He already meets surgical criteria outright; deferring a proven durable option for one with a shorter track record is a real trade, not a free option.
I don't think either of you is actually wrong, which is exactly why this shouldn't become an open-ended trial. Give tirzepatide a real, maximally titrated run — but set the terms now, not later: a defined interval, six months, with explicit A1c and weight-loss targets agreed by everyone in this room today, not renegotiated once we're in it.
If he hits those targets, we've bought him the outcome without the operation. If he doesn't, the surgical referral proceeds immediately, on schedule, with no further "let's give it a bit longer" conversation — the failure mode we're actually trying to avoid isn't picking the wrong option today, it's drifting on the drug indefinitely because neither option was ever formally closed off.
Agreed: tirzepatide started and titrated toward 15mg, basal insulin down-titration protocol established, surgical referral kept open with a firm six-month re-evaluation date and pre-agreed numeric targets (A1c under 7.5%, at least 10% weight loss) documented in the chart before he left the visit.
Not agreed: whether six months is the right interval, or whether it should be shorter given how quickly tirzepatide's early effect typically shows. The endocrinologist would have accepted four months; the surgeon held out for the full six as the minimum needed to judge the drug fairly before reopening the surgical conversation. Six months was set as the working compromise, not because either number was proven wrong.